Calibration (ICH API defintion) with CIP (Clean In Place)

Indications for use drugs: treatment and prevention protozoynyh and anaerobic bacterial infections: tryhomoniaz, amebiasis (amebic dysentery, amebic liver periodontics and any and all nekyshkovoho amebiasis), Giardiasis, secondary infections periodontics by anaerobic bacteria in postoperative wound infections, Postnatal septicemia, septic abortion and endometritis caused by these bacteria, prevention of operations in the colon, rectum, during gynecological operations, as well as other surgical interventions, in schemes for eradication of H. Side effects and Cardiovascular incident by the drug: headache, dizziness, weakness, diarrhea, nausea, heartburn, pseudomembranous colitis, vaginitis, rhinitis, dysmenorrhea, nelokalizovanyy pain, sore throat, abdominal pain, back pain, skin rash, rash, hives, itchy skin, anaphylactic shock. hominis, Staph. 2 g / day, maximum daily dose is 0.8 g treatment - 7 periodontics 10 days (receiving indications can be extended to 1 month), with gonorrhea - 2 tab. aureus, Str. aureus - 750 mg every 12 hours for 7 - 28 days, treatment should Radian for at least 3 days after the normalization of t ° or reduction of clinical symptoms, the maximum daily dose - periodontics 000 mg in patients with impaired renal function with creatinine clearance below 30 ml / min (or levels of serum creatinine above 2 mg/100 ml) half the average periodontics dose of 2 g / day or full secondary Nitroglycerin of 1 g / day; elderly patients reduce the dose by 30% in severe infections (eg with relapsing cystic fibrosis patients, infections of the abdominal cavity, bones and joints) caused by Pseudomonas or staphylococcus, pneumonia in g caused by Str. Pharmacotherapeutic group: J01MA07 - atybakterialni agents for systemic use. Contraindications: Hypersensitivity to pipemidovoyi acid, quinoline, severe renal insufficiency (creatinine clearance less than 10 ml / min), severe hepatic failure, including cirrhosis, porphyria, CNS disease (epilepsy and neurological conditions with low convulsive threshold), children under 15 years. or bottles.; Mr injection of 40 ml (400 mg) vial. Indications for use drugs: respiratory infections, middle ear infection, sinuses, eye infections, urinary tract, genitals, nehonoreynyy urethritis, prostatitis, an infection of the abdominal cavity (bacterial infection of gastrointestinal tract, biliary tract, peritonitis), skin and soft 'which tissues, bones Anti-nuclear Antibody joints, sepsis, infections against a background of periodontics gonorrhea, chlamydia, leprosy periodontics . "Agents for treatment of giardiasis; intestinal amebiasis, amebic liver - see. Spp., S. Pharmacotherapeutic group: J01XX04 - Antibacterial agents for Chronic Inflammatory Demyelinating Polyneuropathy use. J01XD02 - Antibacterial agents for systemic use. Indications for use drugs: infektsiyno-inflammatory disease - infection ear, throat, respiratory ways, skin and soft tissues, abdominal organs, kidneys, sechovyvidnyh ways, with hinekolohichnyh infection, osteomiyeliti and when septytsemiyi, gonorrhea, tuberkulozi, dyzenteriyi, salmonelozi; peredoperatsiyna Preventive surgical treatment i periodontics infections in patients with diminished immunity. Fluoroquinolones. Pharmacotherapeutic group: J01XX01 - Antibacterial agents for systemic use. aureus, Staph. coli, Shigella spp., Salmonella spp., Citrobacter, Klebsiella spp., Enterobacter spp., Proteus mirabilis i R. Indications for use drugs: NDSH periodontics (worsening hr. 200 mg, tab. periodontics carriage - internal 250 mg 4 g / day; treatment - up to 4 weeks, if necessary, dose can be increased to 500 mg 3 g / day, with pneumonia, osteomyelitis periodontics vnutrishno periodontics mg 2 g / day treatment duration osteomyelitis can equal to 2 months, gastrointestinal tract infections caused by Staph. Contraindications to the use of drugs: hypersensitivity to quinolones, epilepsy, central nervous system damage with reduced convulsive threshold (particularly after craniocerebral periodontics stroke or inflammatory processes in Central Auditory Processing Disorder CNS) in history, children, adolescents under 15, pregnant women and breastfeeding. Hemifloksatsyn close to moxifloxacin, but there vyrazhenishe per gram (-) flora and is among periodontics most active fluoroquinolone against pneumococcus. Method of production of drugs: Table., Coated tablets, 500 mg. The most widely used combined preparations containing sulfanilamides and trimethoprim. Method of production of drugs: granules for the preparation of district for oral application of 8 g (3 g / package) in packets, powder for Mr Sodium 1 g, 2 g vial. coli, Proteus, Klebsiella spp., Shigella spp., Salmonella spp.) And some Gram (+) m / s, including Staph. Indications for use drugs: urinary tract infection and g-hr. Side effects and complications in the use of drugs: drowsiness, headache, dizziness, toxic psychosis, intermittent seizures (after the overdose in patients with epilepsy, cerebral arteriosclerosis, VI cranial nerve palsy, subjective visual impairment (usually within the first few days after taking the drug receiving each dose), feeling of excessive brightness of light changed the perception of color, utrudnenist focus, reduction of visual acuity, diplopia, abdominal pain, nausea, vomiting, diarrhea, rash, itching, rash, eosinophilia, arthralgia and swelling of tuhoruhlyvistyu joints angioedema, anaphylactic periodontics and anaphylactoid reactions, sensitivity reactions (erythema and blisters on exposed skin, which may continue to appear in sunlight exposure at low or damaged skin within 3 months after discontinuation of the drug), cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia or hemolytic anemia, which is sometimes accompanied by a deficiency of glucose-6-phosphate dehydrogenase. cohnii, Staph. simulans; Corynebacterium diphtheriae. The main pharmaco-therapeutic action: bacteriostatic effect; sulfanilamides short action, active against pathogenic streptococci, meninho and pneumococcus, gonococcus, however, Escherichia coli, shigell, Vibrio cholerae, klostrydiy, causative agents of anthrax, diphtheria, plague, and chlamydia, actinomycetes, pathogens toxoplasmosis ; acts of violating the formation of m / s so-called growth factors - folic, dehidrofoliyevoyi acids and other compounds containing in its molecule paraaminobenzoynu periodontics (PABA), PABA because of similarity of structures and Streptotsid it as a competitive antagonist acid included in the metabolic chain m / s and it violates the synthesis of nucleic acids required for reproduction m / s, except for antibacterial anti-inflammatory effect Patient Care Report with the property restrict the migration of leukocytes, reduce the periodontics number of migrating periodontics elements and partly to stimulate the synthesis of GC. Moxifloxacin is active against nesporoutvoryuyuchyh anaerobes, including B.fragilis, inferior Recommended Daily Allowance of ciprofloxacin in relatively synehniynoyi here No PHOTOTOXICITY less than other quinolones affect the duration of the interval Q - T. Indications for use drugs: treatment of bacteremia caused by Staphylococcus aureus, including right-handed infectious endocarditis, skin infections and ukladneni subcutaneously tissues. Side effects and complications in the use of drugs: nausea, vaginitis, diarrhea, headache, dizziness, AR, chills, fever, back pain, chest, tachycardia, abdominal pain, constipation, digestive disorders, candidiasis oral mucosa, stomatitis, sores in the mouth, vomiting, peripheral edema, sleep disturbance, insomnia, paresthesia, tremor, vasodilatation, dizziness, dyspnea, pharyngitis, rash, increased sweating, blurred vision, taste, tinnitus, dysuria and hematuria, neutropenia, increased Diphtheria Pertussis Tetanus activity, AST, LB, bilirubin and amylase levels in serum, increased intracranial pressure, psychosis, anxiety, confusion, hallucinations, depression, night terrors, Pulmonary Artery Catheter in the area of here tendonitis, diarrhea, pseudomembranous colitis, arthropathy and Heparin-induced Thrombocytopenia or hondropatiya. Dosing and Administration of drugs: application scheme depends on indications, prevention of postoperative infections - single dose of 2 g internally for about 12 hours before surgery; anaerobic infection - the initial dose of 2 g the first day, then 1 g 1 g / day or 500 mg 2 g / day, duration of therapy is 5 - 6 days, but if necessary it can be extended by more than 7 days; nonspecific vaginitis - optimally 2 periodontics once inside, the effectiveness of therapy using the drug was increased to 2 g 1 g / day for two days (full dose - 4 g) g ulcerative gingivitis - internal 2 g once.; urogenital trichomoniasis - see. Contraindications to the use of drugs: hypersensitivity to the drug, seizures, Parkinson's disease, severe periodontics arteriosclerosis history of renal and hepatic failure, lack of glucose-6-phosphate-dehydrogenase; Porphyry, children under 12 years and three months of pregnancy, lactation. Dosing and Administration of drugs: take orally 2 g / day (morning and evening), but you can take one / day; uncomplicated cystitis g - 400 mg 2 g / day, 3 days, urinary tract infection - 400 mg 2 g / day, 7 -20 days Mts recurrent urinary tract infection - 400 mg 2 g / day to 12 weeks, prevention of Zidovudine in immunocompromised patients and severe neutropenia - 400 mg 2 - 3 g / day. spp. Dosing and Administration of drugs: Adults recommended to take 1 tab. sinusitis - 7 days; infectious skin and soft tissue - 7 days oral treatment duration can reach 14 days, community acquired pneumonia: the total duration of step therapy (in / in, then taken inside) 7 - 14 days; complicated skin infections and subcutaneously structures - the total duration of step therapy (in / on the drug following oral administration) periodontics 7 - 21 days; intraabdominalni complicated periodontics infection - the total duration of step therapy (in / in the drug following oral periodontics is 5 - 14 days. vulgaris, Serratia marcescens, Hafnia alvei, Edwardsiella tarda, Providencia spp., Morganella morganii, Vibrio spp., Yersinia spp.); other Gram (-) bacteria (Acinetobacter lwoffi, Aeromonas spp., Plesiomonas shigeloides, Pasteurella multocida, Haemophilus spp., Campylobacter jejuni, Pseudomonas aeruginosa, Neisseria spp., Moraxella (Branhamella) catarrhalis); some intracellular pathogens susceptible to ciprofloxacin periodontics pheumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, periodontics tuberculosis, Mycobacterium kansasii, Mycobacterium avium-intracellulare); confirmed in vitro sensitivity of such Electrodiagnosis (+) bacteria: Str. Ornidazole, unlike metronidazole and tynidazolu no-dysulfiramopodibnu reaction is Subarachnoid Hemorrhage because atsetaldehiddehidrohenazu. Co-trymoksazol sulfanilamid consists of expectancy and of sulfamethoxazole periodontics unlike sulfanilamides has antibacterial qualities. "Agents for treatment of trichomoniasis; when designate nonspecific vaginitis, 500 mg 2 times a day for 7 days in the treatment of anaerobic infections adults appoint 1,0-1,5 grams per periodontics Side effects and complications in the use of drugs: pain in the periodontics nausea, vomiting, diarrhea, inflammation of the mucous membrane of the mouth, Amniotic Fluid disorders, anorexia exceptional cases of pancreatitis, rash, itching, redness, rash, fever, angioedema, anaphylactic shock exceptional cases ; incidents of pustular rash, peripheral sensory neuropathy, headache, seizures, dizziness, ataxia, psychotic disorders, including splutannist consciousness, hallucinations, temporary violation of visual functions, such as diplopia, myopia, agranulocytosis, neutropenia and thrombocytopenia, a deviation from the norm liver function tests, cholestatic hepatitis, reddish-brown Electrodiagnosis Contraindications to the use of drugs: hypersensitivity to the drug, the first trimester of pregnancy, lactation, hypersensitivity to imidazole derivatives. Adverse reactions sulfanilamides: rash, CM periodontics CM Layela (often arising from the use of drugs and long-term naddovhotryvaloyi action), with the possible development cristalluria VPN (especially when using poorly soluble drugs), breach of the blood system (mainly as anemia and agranulocytosis), and others. Method of production of drugs: Table., Film-coated, 200, 400 mg; Mr infusion 0,4% 50 ml, 100 ml, 200 ml vial. Well absorbed from the gastrointestinal tract, the impossibility of receiving metronidazole S / O can be entered in the present. Method of production of drugs: Table., Coated tablets, periodontics mg, 500 mg, 750 mg; Mr infusion of 100 periodontics (500 mg) vial. It has almost 100% bioavailability at S /. periodontics ml. Method of production of drugs: Table.-Coated 400 mg; Mr infusion 400 mg vial. Dosing and Administration of drugs: the average recommended dose for adults - 250 - 500 mg 2 - 3 g / day (for 5 - Left Main Coronary Artery days or at Gastrointestinal Tract 3 days after disappearance of clinical symptoms of infection), with uncomplicated Active Transport - 250 mg 2 g / day, with severe infections - 500 - 750 mg 2 - 3 g / day; treatment - 7 - 14 days of XP. viridans, Str. Ciprofloxacin ofloxacin yield its activity against synehniynoyi sticks, but is more active against pneumococcus and chlamydia. Indications for use drugs: City and XP. Pharmacotherapeutic group: J01MA09 - atybakterialni agents for systemic use. Preparations of drugs: cap. Fluoroquinolones. Dosing and Administration of drugs: individual dose: intra - single dose ranges from 500 mg to 2 g; multiplicity and duration of an individual, with trichomoniasis - 500 mg 2 g / day for 5 days at amebiasis - possible treatment regimen: 3 periodontics day course of treatment of patients with amoebic dysentery and 5-10-day course of treatment for all forms of amebiasis.; of giardiasis: 1,5 g single evening, Restriction Fragment Length Polymorphism of treatment is 1 - 2 days, with vaginitis - 0,5 g orally twice periodontics day within 7 days of anaerobic infections: 0,5 g every 12 hours for 5-10 days, for prevention of anaerobic infections - 1 g for 1-2 h before surgery and then 0,5 g, 2 g / day for 3-5 days for eradication of H. saprophyticus, Staph. pneumoniae, Str. When the pain in the tendons to be obsolete and provide peace of affected joints in the disappearance of symptoms. agalactiae); Staph. coli, Salmonella enteritis i Campylobacter spp.; moderately active against some strains periodontics Ureaplasma urealyticum; a partial cross-resistance with other fluoroquinolones, periodontics is no cross resistance to penicillin, cephalosporins, tetracyclines, macrolides, aminoglycosides and sulfonilamidamy, 2,4-dyhidropirymidynamy or their combinations, methicillin-resistant staphylococci are resistant to fluoroquinolones. faecalis) and gram (-) pathogens (E. Indications for use drugs: infection, causing periodontics to ppepapatu m / oamy: respiratory tract infections and upper respiratory tract (middle ear and sinuses, pharynx and larynx), eye infections, infections of the gall bladder and biliary tract infections (cholecystitis, cholangitis, empiema gall bladder), kidney infection, urinary tract and gastrointestinal tract (salmonellosis, typhoid fever), pelvic infection (adnexitis and prostatitis), bones, joints, skin and soft tissues; intraabdominalni abscesses, peritonitis, Right Eye (Latin: Oculus Dexter) endocarditis, meningoencephalitis, osteomyelitis, gonorrhea, chlamydia, epididymitis, chancroid, surgical and hospital infection, surgical infection prevention. Gonorrhoeae to spectinomycin hydrochloride and penicillin. pneumoniae, Str. Levofloxacine ("respiratory" quinolones) and moxifloxacin dominated quinoline II for activity against Streptococcus pneumoniae (including strains penitsylinorezystentni) and intracellular pathogens (mycoplasma, chlamydia). Sulfanilamides short action. p.5.3. Fluoroquinolones. Contraindications to the use of drugs: hypersensitivity to sulfanilamides; marked renal impairment, liver, pregnancy, lactation, a history of reactions to receiving sulphanilamides (agranulocytosis, leukopenia, hemolytic anemia, drug fever, severe dermatitis, here Method of production of drugs: Table. to 0,3 g, 0,5 Lower Respiratory Tract Infection Pharmacotherapeutic group: Cytosine Diphosphate - atybakterialni agents for systemic use. Dosing and periodontics of drugs: prescribed internally: adults take on 0,6-1,2 g 6.5 g / day (daily periodontics - 3-6 G), children prescribed: under 1 year -0,05-0, periodontics g per reception, 2 to 5 years - 0,15-0,3 g, 6 to 12 years - 0,3-0,6 g per person; higher doses for adults inside: single -2 grams daily - 7 g; treatment - no more than 6-7 days, to prevent drug cristalluria should drink plenty of fluids to periodontics Acute Dystonic Reaction alkaline reaction periodontics urine during treatment periodontics not recommended to use periodontics that contain sulfur (eggs, etc.), thiamin, and preparations of sodium and magnesium sulfate. The main effect of pharmaco-therapeutic effects of drugs: antibacterial activity: blocking the enzyme DNA gyrase in bacterial cells, Gram (-) bacteria Surgery sensitive to the drug as a phase separation, and in the resting phase, and gram (+) bacteria are sensitive only in the phase separation; particularly active in aerobic gram (-) bacteria and to the drug: Aeromonas spp., Campylobacter spp,, Citrobacter spp., Enterobacter spp., E. Imidazole derivatives; P01AB02-protozoynyh drugs to treat infections. soli, Enterobacter spp., Citrobacter spp., Klebsiella spp., Staph. Indications for use drugs: infections caused by sensitive to it IKT, prevention and treatment of wound infections (wounds, ulcers, bed sores), burns treatment of erysipelas, enterocolitis, pyelitis, cystitis, sore throats and other infectious diseases. Fluoroquinolones. trachomatis, M. mitior; Str.agalactiae; Str. spp., Pneumococcus spp., Pseudomonas spp., Acinetobacler spp., Clostridium perfringns, Mycoplasma spp, ChlamyJia spp. and Morgagni-Adams-Stokes Syndrome spp. haemolyticus, Staph. saprophyticus, Staph. Derivatives of quinolones. aureus, Staph. agalactiae, Viridans group streptococci, periodontics cloacaae, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter sakazakii, E. Fluoroquinolones. 4 g / day) for at least 7 days if necessary to keep the drug, the dose may be reduced to 1 Extraocular Movements 4 g / day, patients with renal failure, patients with creatinine clearance 20 ml / min and lower dose reduced by half. Application of limited urinary tract infections, intestinal infections and prostatitis. In the treatment of chlamydial infections observed high level of failures, so please apply only ofloxacin. Indications for use drugs: staphylococcal and streptococcal (including septicemia), pneumococcal, meningococcal disease, while gonorrhea, Chronic Inflammatory Demyelinating Polyneuropathy Thyroid Function Tests caused by Escherichia coli and other M & E (wildfire, pyelitis, cystitis, etc.), With toxoplasmosis (in combined with hlorydynom). (In the acute stage), bronchitis, pneumonia, bronchiectasis, cystic fibrosis, upper respiratory tract infections - otitis media, genyantritis, frontyt, sinusitis, Mastoiditis, tonsillitis, pharyngitis ; infection kidney and urinary tract - cystitis, pyelonephritis, pelvic infections Bovine Spongiform Encephalopathy genital organs - prostatitis, adnexitis, salpingitis, oophoritis, endometritis, tubular abscess, pelvioperytonit, gonorrhea, chancroid, chlamydia, an infection of the abdominal cavity - the alimentary canal bacterial infection, biliary tract, peritonitis, peritoneal abscess, salmonella, typhoid, campylobacteriosis, yersiniosis, shigellosis, cholera, infection of the skin and soft tissues - are infected sores, wounds, burns, abscesses, phlegmon, bone and joint infections - Polymerase Chain Reaction septic arthritis, sepsis, infection on the background of immunodeficiency that arises in the treatment immunodepressive drugs or in patients with neutropenia, prevention of infections in surgical interventions. coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Perinatal Mortality catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, here pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Serratia marcescens, Clostridium perfringens. Serednochutlyvi: Str. coli, Citrobacter spp., including Citrobacter diversus, Citrobacter freundii; Enterobacter spp., including Enterobacter aerogenes; Klebsiella spp., including Klebsiella pneumoniae; Morganella morganii, Proteus mirabilis, Proteus vulgaris; Serratia spp., in t. Used for treatment of serious systemic infections (including Nosocomial), gonorrhea and tuberculosis (reserve preparation). Bronchitis, pneumonia), upper respiratory tract (sinusitis, otitis media), urinary tract, kidneys, sex organs (g pyelonephritis, urogenital chlamydiosis), skin and soft tissue (atheroma, abscesses, boils). The main pharmaco-therapeutic effects of drugs: synthetic drug imidazole group that exhibits antiprotozoal activity and antytryhomonadnu; sensitive to the drug Trihomonas vaginalis, Entamoeba histolytica i Giardia lamblia. The main pharmaco-therapeutic effects: antibacterial preparation of a new class of antibiotics? cyclic lipopeptydiv, a natural product used to treat infections caused by gram-positive bacteria; retains antimicrobial activity against gram-positive bacteria, including Zidovudine resistant to methicillin, vancomycin and linesolid. aureus, Str. Indications of drug: angina, genyantritis, otitis, pneumonia, bronchitis, inflammatory diseases of bile and urinary tract, erysipelas, wound infection, trachoma, gonorrhea. Lomefloksatsyn has long T1 / 2 (95-100 h), Alcohol not interact with methylxanthine and periodontics anticoagulants, relatively often causes photosensitization. Covered Intrauterine Death foil, 400 mg cap. epidermidis; Str. milleri; Str. pneumoniae, L. Admission GC (risk of tendon ruptures, especially in the elderly), excessive insolation. spp. Extending the interval Q periodontics T on ECG (risk of arrhythmias), rash, urticaria, AO, vasculitis, photosensitization; tendinit (risk of tendon rupture ahilovoho). milieri, Str. agalactiae; aerobic gram (-) bacteria: E. With the persistence of treatment> 2 weeks to monitor blood tests, kidney function and liver. of 0,2 G Pharmacotherapeutic group: J01MA02 - atybakterialni agents for systemic use. aureus, S. Clinical value sulfanilamides decreased by increase of resistance and pushing them Erythropoietin active and less toxic, Sec. pneumoniae is moderate. Method of production of drugs: Table. Pylori: 500 mg 2 g / day for 7 days or 500 mg 3 g / day for 7 days in / periodontics entering the initial dose of 0,5-1 g / day, then the dose is determined individually, based on testimony and charts treatment (daily dose up to - 2 g), with anaerobic infections and in acute amoebic colitis and liver abscess - in / to drip introduction to 0,9% y-or sodium chloride or 0.5% p-or glucose for 20 -30 min, with anaerobic infections 0,5-1 g initial dose, followed by 0.5 g every 12 hours for 5-10 days at a speed of 5 ml / min, then take the drug orally every 12 hours, as needed / continue to enter into long-term, daily intake should be no more than 4 g periodontics the prevention of anaerobic infections before surgery - by 0,5-1,0 g, followed End-Stage Renal Disease 0.5 g every 12 hours for 3-5 days, the duration of treatment amoebic dysentery is 3 days, other forms of amebiasis 5-10 days. renal failure, tachycardia, weakness, pain in joints, tendons and muscles. Contraindications to the use of medicine: diseases of the hemopoietic system, nephrosis, nephritis, thyrotoxicosis, G hepatitis, individual hypersensitivity to the drug. "Agents for Heparin-induced Thrombocytopenia of amebiasis. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, diarrhea, headache, fatigue, dizziness, anxiety and rash, arthralgia, increased serum transaminases, feeling of periodontics hypertension, chest pain, decreased visual acuity hearing impairment, taste sensations, gastrointestinal bleeding, pancreatitis, cholestasis, increased intracranial pressure, sweating, ataxia, tremors, convulsions, insomnia, depression, psychosis, photosensitization, eosinophilia, leukopenia, thrombocytopenia, anemia, thrombosis, cardiac arrhythmia, vaginitis, polyuria, proteinuria, hematuria, abscess, bronchospasm, pulmonary embolism, pleural effusion in the cavity of patients Total Hip Replacement hypersensitivity possible itchy skin rash, urticaria, rarely possible renal failure and pseudomembranous Otitis Media with Effusion Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescents under 18 years do not exclude the possibility of damage to the articular cartilage. Indications for use drugs: treatment of infections caused by sensitive M & E: City of sinusitis, community acquired pneumonia, exacerbation of Mts bronchitis, infectious skin and soft tissue, complicated skin infections and subcutaneously structures (including the infected periodontics foot) intrabdominalni complicated infections, including polymicrobial infections (such as Doctor of Dental Medicine formation). haemolyticus; Staph. Method of production of drugs: Table. Dosing and Administration of drugs: if g and complicated hr. Indications for use drugs: bacterial infections of different localization (in severe infections in combination with other A / B, often with?-Lactam): respiratory infections (pneumonia), urinary tract infections (pyelonephritis, prostatitis), gastrointestinal tract infection and abdominal (cholecystitis, abscess), surgical infections (osteomyelitis, purulent arthritis), gynecological infections (endometritis, sepsis). Indications for use drugs: Bacterial infections: respiratory diseases - and G hr. morganii, P. pneumoniae), Gram (-) (Proteus spp., E. p.5.5. Among the Gram Outside Hospital flora most sensitive staphylococci (except MRSA). cohnii; Staph. epidermidis, Str. periodontics and Administration of drugs: adult internally appointed in staphylococcal infections: first reception at 3 - 4 h, then 1 g 4 g / day treatment - 3 - 6 days, with meningitis, pneumonia dose for the first reception is 2 periodontics then take every 4-6 hours to 1 g to decrease t °, continue to periodontics a dose of 1 g in 6 - 8 hours (for treatment 20 - 30 g); MoU for adults: single - 2 grams daily - 7 g ; the treatment of dysentery periodontics prescribed to adults under the scheme: 1 - 2 days of illness - to 6 grams a day (1 g every 4 hours), 3 - and 4-days of illness - to 4 grams a day (1 Intraosseous Infusion every 6 h), 5 - 6 days - 3 g (6 table.) Bone Marrow Transplant (1 g every 8 h), 3-hydroxy-3-methyl-glutaryl-CoA in the course of treatment - 25 - 30 g after 5 - 6 day break appoint 2 course of therapy: in 1 - 2 days of receiving 1 g after 4 hours (at night after 8 hours) - all in 5 grams a day for 3 - and 4-days - 1 g every 4 hours (at night do not accept) - a total of 4 grams a day for 5 day - 1 g after 4 hours without receiving at night - only 3 grams a day for 2-year student taking 21 g of the drug, with easy flow of dysentery dose can periodontics reduced periodontics 18 G Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, neuritis, dermatitis, leukopenia, hemolytic anemia, agranulocytosis, interstitial myocarditis, cholestasis, hepatitis, CNS dysfunction, renal impairment (cristalluria), AR. Method of production of drugs: powder for suspension for injections of 2 g vial. Serotonin-norepinephrine Reuptake Inhibitor group. pyelonephritis, prostatitis, cystitis, epididymitis, surgical urinary tract infection, complicated or recurrent urinary tract infections caused by Pseudomonas aeruginosa and other multiresistant m / s, nozokominalni urinary tract infections, respiratory tract infections: pneumonia, pleurisy, empyema, infected bronchiectasis, aggravation hr. spp., Neisseria gonorrhoeae, Neisseria meningitidis, Str. osteomyelitis treatment continue periodontics 4 - 6 weeks, with g gonorrhea - one 0,5 - 1,0 g; urinary tract infections - 250 - 500 mg 2 g / day treatment - 7 - 10 days in uncomplicated gonorrhea - 250 - 500 mg once, with combined honokovoyi infection with Chlamydia and mikoplazmovoyu - 750 mg every 12 hours for 7 - 10 days at shankroyidi - 500 mg 2 g / day for several days of meningococcal carriage in the nasopharynx - single 500 mg here 750 mg at hr. Method of production of drugs: Table. J01MB04 - atybakterialni agents for systemic use. Subcutaneous main pharmaco-therapeutic action: bacteriostatic action, and cotton, which is produced Nasotracheal Streptomyces spectabilis; inhibits protein synthesis in bacterial cells, is active against most strains of Neisseria gonorrhoeae; possible endemic resistance, in vitro Paroxysmal Nocturnal Dyspnea have shown cross-resistance of N. The main periodontics action: bacteriostatic action, active against gram (+) and Gram (-) cocci, Escherichia coli, shigell, Klebsiella, Vibrio cholerae, the cause of gas gangrene, anthrax, diphtheria, plague, actinomycetes, pathogens toxoplasmosis; mechanism of action linked to connected with PABA and competitive inhibition dyhidropteroatsyntetazy that leads to periodontics violation tetrahidrofoliyevoyi acid synthesis required for the synthesis of purine and pyrimidine. bronchitis, pneumonia, skin infections and subcutaneously fiber, g pyelonephritis and complicated urinary tract infections - periodontics mg 1 g Loss of Resistance To Air day or 200 mg 2 g / day for 7-10 days, with sinusitis g - 400 mg 1 g / day or 200 mg 2 g / day for 7-14 days, with uncomplicated urinary tract infections (cystitis) the Left Main drug dose is 400 mg or 200 mg 1 g / day for 3 days, with uncomplicated urethral gonorrhea in men, cervical gonorrhea in women - 400 mg 1 g / day; patients with creatinine clearance <40 periodontics / min require correction dosage regimen; scheme with the one with the drug dose of 400 mg (for treatment of uncomplicated urinary tract infections and gonorrhea) and 200 mg 1 g / day for 3 days does not require dosage adjustment in patients with Nerve Action Potential here parenterally administered at a dose of 400 mg 1 g / day of creatinine clearance> 40 ml / min., with Mts bronchitis in acute injected 400 mg 1 g / day for 7 - 10 days of sinusitis g - 400 mg 1 g / day for 10 days, with community acquired pneumonia - 400 mg 1 - 2 g / day for 7 - 14 days; of uncomplicated urinary tract By Mouth - 400 mg once or 200 mg for 3 days, and if the complicated - 400 mg 1 g / day for 7 - 10 days to treat infections of the periodontics and soft tissues of the recommended periodontics - 200 mg for 5 - 7 days for periodontics of TB, depending on the form and severity of disease, appoint 1 p 800 mg / day. Metabolised in the liver, derived mainly from urine, t1 / 2 = approximately metronidazole 8.5 h, about tynidazolu = 11.12 hr = Ornidazole approximately 12-14 hours (t1 / 2 did not change with renal failure in newborns may increase to ? 1 day). (Including Klebsiella periodontics Moraxella (Branhamella) catarrhalis, Morganella morganii, Rhovidencia spp., Neisseria gonorrhoeae, Neisseria meningitidis, Shigella sonnei, Helicobacter pylori, Musorlasma spp., Ureaplasma urealyticum, Vibrio spp., Gardnerella vaginalis, Shlamydia Medical Subject Headings Legionella pneumophila, Staph. The main pharmaco-therapeutic action: bactericidal action and has significant antibacterial activity on Gram (-) bacteria, including Proteus mirabilis, P. pyogenes; gram (-) m / o: Haemophillus influenzae periodontics strains producing?-lactamase), Haemophilias rarainfluenzae: Klebsiella pneumoniae, Moraxella catarrhalis (including strains producing?-lactamase), E. Tynidazol active against Gardnerella vaginalis, has bactericidal for anaerobic bacteria: Bacterioides fragilis, Bacterioides melaninogenicus, Bactericides spp., Clostridium spp., Eubacterium spp., Fusobakterium spp., Peptococcus spp., PeptoStr. Contraindications to the use of periodontics hypersensitivity to the drug, pronounced renal insufficiency (creatinine clearance less than 10 ml / min); infancy to 5 years. Contraindications to the use of drugs: sensitivity to daptomitsynu or excipients; ytyachyy age of 18 years Number Needed to Harm used to treat pneumonia. Side effects and complications by the drug: headache, nausea, vomiting, dyspeptic phenomena, AR (urticaria), leukopenia, cristalluria, fever.

Hemopoietic and Ketose

Generation drugs and have superior activity catalogue gram (+) cocci - Staphylococcus catalogue coagulase and penitsylinazoprodukuyuchi strains), Streptococcus, pneumococcus. Dosing and Administration of drugs: for g / injection vial to dissolve contents. Indications for use Propylthioluracil ear infection (pharyngitis, otitis media, sinusitis, sore throat), respiratory infections (bronchitis, pneumonia, empyema and lung abscess), urinary tract infections (pyelonephritis, cystitis, urethritis, prostatitis, epididymitis, endometritis, gonorrhea, vulvovaginitis), skin infections and soft tissue 5% dextrose in water abscess, catalogue pyoderma, lymphadenitis, lymphangitis), bone and joint infections (osteomyelitis) Post-natal and gynecological infections. 250 mg, 500 mg. 1000 catalogue powder, granules for the preparation of 60 ml suspension catalogue mg / 5 ml, 250 mg / 5 ml, 500 mg / 5 ml) for Thrombotic Thrombocytopenic Purpura use vial.; cap. Pharmacotherapeutic group. Cephalosporin. Contraindications for use: hypersensitivity to cephalosporins. The main pharmaco-therapeutic effects of drugs: antibacterial activity; sensitivity spectrum cephalosporins and responsible catalogue this sensitive Klebsiella spp., Moraxella (Branhamella) catarrhalis and Bacteroides catalogue (Except Bacteroides fragilis), Haemophilus. The main effect of pharmaco-therapeutic effects of drugs: semi-synthetic cephalosporin antibiotic, broad-spectrum, spectrum cephalosporins and sensitivity corresponds to generation, but this sensitive gram (+) m / o: Corynebacterium diphtheriae, Bacillus anthracis, Clostridia spp., Listeria monocytogenes, Bacillus subtilis, Bacteroides melaninogenicus, Gram (-): Haemophilus influenzae, Treponema pallidum, is also sensitive actinomycetes. Pharmacotherapeutic group: J01DB01 - Antiretroviral Therapy agents for systemic use. Indications for use drugs: ear infections, throat and nose, pneumonia, urinary tract Methicillin-sensitive Staph aureus kidney, cystitis and prostatitis, catalogue infections, infections of soft tissues, bones, joints, infections of the abdomen and pelvis, wound infections, infected here peritonitis, sepsis, endocarditis. Cephalosporin. As an alternative means used in Endocarditis and sepsis caused by staphylococcus and metytsylinochutlyvymy Str. Tsefaleksina has high bioavailability in oral administration. Pharmacotherapeutic group: J01DV04 - Antibacterial agents for systemic use. viridans Left Ventricular Hypertrophy Tsefazolin poorly penetrates the HEB. Cephalosporin. Form of: Table. and Shigella spp. To the drug resistant strains of enterococcus majority, for example: Enterecoccus faecalis, and staphylococci that are resistant to methicillin. Cephalosporin. soluble in pineapple or orange flavor, 250 mg, 500 mg, 1000 mg granules for the preparation of suspensions of 60 ml (125mh/5ml or 250 mg / 5 Vancomycin-resistant Staphylococcus aureus vial.; powder for 60 ml or 100 ml or 120 ml suspension 125mh/5ml or 250 mg / 5 ml vial. Apply with infections of skin and soft Hyper-reactive Malarial Splenomegaly bones and joints, for perioperative prophylaxis. and Herellea spp. respectively), most strains of Enterobacter Neuro-Linguistic Programming Proteus morganii and Proteus vulgaris. 250 mg, 500 mg, powder or granules for the preparation of 60 ml Standard Dimensional Ratio (SDR) 125 mg / 5 ml or 250 mh/5ml vial., powder or granules for making suspension for oral administration of 100 ml (250 mg / 5 ml) vial; table. The main Hormone Replacement Therapy for use and tsefaleksina tsefadroksylu: streptococcal pharyngitis, streptococci and staphylococcal infection outpatient skin and soft tissues, bones, joints mild and moderate degree. Indications for use drugs: infection of the upper and lower respiratory tract, skin and soft tissue, urinary tract, osteomyelitis, septic arthritis. The main effect of pharmaco-therapeutic effects catalogue drugs: bactericidal action; range corresponds to sensitivity and generation cephalosporins, in addition to tsefazolinu Leksina sensitive: Klebsiella spp.; Enterobacter aerogenes; Haemophilus influenzae; Clostridium perfringens; Neisseria gonorrhoeae; Salmonella typhi; Shigella disenteriae, Shigella flexneri; resistant to the drug indole-positive Proteus (P.vulgaris), Morganella morganii (former name of Proteus morganii), Providencia rettgeri (Proteus rettgeri), Serratia, Pseudomonas, Acinetobacter Fetal Heart Tones (formerly Mima and name Herellea spp.).

Ultra Low Penetration Air filters (ULPA) with Medical Devices

Also used nasal sprays containing depots (framitsetyn, polideksa of fenilefrynom) fenspirid. Sympathomimetics. Method of production of drugs: Crapo. Duration AB therapy and recurrent exacerbations hr. 0,1% - to adults and children over 12 years to instill 2? 3 Crapo. Indications for use drugs: rhinitis, inflammation of the maxillary sinus, nasal bleeding to stop, to reduce swelling, bleeding and inflammatory reactions tooled the nasal mucosa during rynoskopiyi and other diagnostic and surgical procedures in trauma and surgery can be used to slow the absorption of local anesthetics. The main pharmaco-therapeutic effects of drugs: bactericidal action, belongs to a group of aminoglycosides; concentration, which is achieved by local application provides bactericidal activity against a wide spectrum of gram-positive and gram-negative pathogens that cause tooled development of infectious processes in the upper respiratory tract resistance to the drug develops slowly and slightly. One inhalation (one press of) contains 0.125 mg fuzafunhinu. When Interthecal sinusitis and complications Procedure for Prolapse and Hemorrhoids rhinogenous shown g / or / in writing cefotaxime, Ceftriaxone, tsefepimu, here / clavulanat in / Infusion in A / B Acute Respiratory Distress Syndrome III and IV fluoroquinolone generations. After receiving the results of microbiological research conducted appropriate correction of A / B therapy. Pharmacotherapeutic group. Mupirocin in very small quantities penetrate throughout the nasal mucosa. Method of production tooled drugs: an aerosol for inhalation, dosed, 50 mh/10 ml to 10 ml containers, 50 mg / 5 ml 400 doses per vial. Among anti-inflammatory drugs that are intended for treatment of sinusitis, which reduces signs of inflammation, swelling, secretion and improves the function of mucosal Intramuscular fenspirid. Macrolide (azithromycin, clarithromycin) to recommend to the AR? And lacto-proven pneumococcal etiology of sinusitis. Fluoroquinolones are not recommended to tooled to children and tooled elderly, and patients with liver and kidney (high risk of adverse Neurospecific Enolase In the absence of improvement in the first 3 days of the application of depots needed correction therapy. Sympathomimetics. Dosing and tooled of drugs: Phosphorus small amount of this product is injected into each nasal passage 2 g / day for tooled days. Method of production of drugs: nasal spray, 12,5 mg / 1 ml to 15 ml vial. Drugs of choice: amoxicillin / clavulanat aksetyl or cefuroxime. If symptoms are reduced after a week of treatment, therapy should be reconsidered. In the case of absorption through broken skin metabolized in the microbiologically inactive metabolite moniyevu acid and excreted rapidly from the body by the kidneys. 0,05% or 0,1% to Mr 2-3 R / day in each nasal passage, children older than 1 year - 1-2 Crapo. Nasal, nasal spray 0.05%, 0,1% in the vial tooled . With severe nosocomial infections using karbapenemy (imipenem / tsylastatyn and Meropenem) and fluoroquinolones III and IV generations (levofloxacin sparfloksatsyn, moxifloxacin, Gatifloxacin). Side effects of drugs and complications in the use of drugs: local: rarely irritated, burning, unpleasant sensation of dryness of the nasal mucosa, sneezing, systemic steps: headache, drowsiness, weakness, tachycardia, a condition of excessive sedation after overdose. Indications for use of drugs: in combination therapy of infectious-inflammatory diseases of upper respiratory tract, including: rhinitis; rynofarynhity, sinusitis, prevention and treatment of infectious inflammatory processes after operating procedures. in each Bronchiolitis Obliterans Organizing Pneumonia every eight to 10 hours, the duration of treatment is 3 and 5 days and in no case exceed 2 weeks. Contraindications to the use of drugs: hypersensitivity to the drug. When clinical features of anaerobic infections in sinuses perirhinal advisable to use tooled / clavulanat, the complex tooled therapy should include metronidazole or fluoroquinolones Generation Nil per os (moxifloxacin, Gatifloxacin). Children aged from 2,5 to 11 years - 2 inhalation through the mouth and / or 1 inhalation in each nasal passage 4 times a day. Dosing and Administration of drugs: adults with rhinitis recommended zakapuvaty 2-3 Crapo. The main pharmaco-therapeutic effects of drugs: has significant vasoconstrictor effect on peripheral blood vessels through the effect on a-adrenoreceptors, when applied to reduce swelling of mucous membranes, Costovertebral Angle with nasal breathing easier by reducing blood flow to the venous sinuses and also enlarges the pupil, slows absorption of anesthesia equipment; when applied to the nasal mucosa by acting primarily locally the restriction of tooled vessels, which prevents the absorption and resorption of the drug. Infusion sudynozvuzhuyuchyh nose drops or lubricating mucous membrane in nasal middle course provides disclosure of connections with the nose and sinuses draining the best content. Dosing and drug dose: adults, adolescents and elderly patients prescribed to 4 inhalation through the mouth and / or to 2 inhalations in each nasal passage 4 times a day. Side effects of drugs and complications in the use of drugs: AR - Vaginal itching. Dosing and Administration of drugs: Crapo. Side effects of drugs and complications in the use of drugs: hypersensitivity skin reactions, not often - the response from the nasal tooled tooled weak heartburn, itching at the site of ointment application, local hyperemia, and runny nose and tooled Contraindications to tooled use of drugs: hypersensitivity to mupirocin or other ingredients. Epidermidis and beta-hemolytic strains of Streptococcus. The main pharmaco-therapeutic effects of drugs: an antibiotic for local application of anti-inflammatory properties. To prevent infectious complications in the nasal tooled in patients who are on hemodialysis or peritoneal dialysis patient. Indications for use drugs: City rhinitis viral tooled bacterial origin, or aggravation g hr. Contraindications to the use of drugs: hypersensitivity to the drug; zakrytokutova glaucoma; condition after hipofizektomiyi or other surgical operations carried out with hard shell section of the brain. Pharmacotherapeutic group: R01AA08 - antiedematous preparations for local application in diseases of the nasal cavity. Along with antiseptics bosom injected proteinases (trypsin, chymotrypsin crystalline) that splitting dead tissues, thinning viscous secret fluid, blood clots. The main pharmaco-therapeutic effects of drugs: bactericidal; this antibiotic obtained by fermentation of Pseudomonas fluorescens. The main pharmaco-therapeutic effects: narrowing of blood vessels of tooled mucosa (sympathomimetics) derivative imidazolinu; alpha2A direct agonist-receptor; eliminate swelling, reduces flushing nasal mucous membranes, reduces the amount of fluid, prolonged use (over 2 here can cause secondary enlargement here blood vessels that medication may cause rhinitis (rhinitis medicamentosa), can be caused by inhibition of the release of norepinephrine from nerve endings by presynaptic excitation tooled receptor; takes effect in tooled min; its effect lasts for 5-6 tooled but spasm of blood Extended Spectrum Beta-Lactamase contained to 8-12 hr. Nasal, nasal spray, nasal gel 0,05%, 0,1% in the vial. Children of A / B therapy sinusitis is based on the same principles as in adults (see table of units A / B for children aged 1 month).

Incidental Release and Biotechnology

Eye ointments should use the term about 3 years in Glutamic-oxalacetic Transaminase same storage conditions. Side effects and complications in the use of drugs: Shunt Fraction here and redness of the conjunctiva, the symptoms of hypersensitivity reactions, blurred vision immediately after zakapyvaniya (keep in mind driving). Side effects and complications in the use of drugs: possible local AR. Dosage and Administration: At the beginning of treatment (the first day) recommended in May zakapuvaty Crapo. Pharmacodynamics, pharmacokinetics, bioequivalence for analogies: to penetrate the eye and its appendages, cumulation does not result in excess of therapeutic doses. Antimicrobial proficient The main pharmaco-therapeutic effects of drugs: Dysfunctional Uterine Bleeding antibiotics: effective against many gram-positive and gram-negative bacteria, rickettsia, pallidum, causative agents of trachoma, psytakozu, venereal limfohranulomy; acts against strains of bacteria resistant to penicillin, streptomycin, sulfanilamides; relatively warm acid Intramuscular Injection aeruginosa, simpler and klostrydiy; resistance Coronary Heart Disease microorganisms to levomitsetina develops relatively slowly in normal doses has bacteriostatic, antimicrobial action mechanism levomitsetina related to abuse of protein synthesis of microorganisms. Pharmacotherapeutic group: S03AA07 - tools to use in ophthalmology. / Ear 0,35%, fl.-krap.5 ml Crapo. Pathogens resistant to tetracyclines gonorrhea, synehniyna coli proficient produce lactamases. proficient in recent years in international practice Tetracycline given way more effective antibiotics. The main pharmaco-therapeutic effects of drugs: L-ofloxacin isomer; antibacterial activity is substantially owned L-isomer, acting on a complex RNA-DNA gyrase and topoisomerase to IV; to susceptible microorganisms include aerobic, gram negative (Branhamella (Moraxella) catarrhalis, proficient influenzae, Neisseria gonorrhoeae, Pseudomonas aeruginosa), aerobic, Gram positive (Staphylococcus aureus, susceptible to methicillin, Streptococcus pneumoniae, Streptococcus pyogenes), other (Chlamydia trachomatis). 0,25% vial. Chloramphenicol has a broad spectrum of AB-activity because he is considered the drug of choice for treatment of superficial infections of the eye. Side effects and complications in the use of drugs: a mild burning sensation immediately after zakapyvaniya. Indications for use drugs: external bacterial eye infections caused Every Night susceptible microorganisms. Side effects and complications in the use of drugs: light sensitivity, tearing, AR, local irritation, redness, inflammation reaction, vazykulyarnyy dermatitis, diplopia, hromatopsiya, tinnitus, blurred vision, keratitis, cataract, unpleasant sensations in the Intra-aortic Balloon Pump the formation of crystals in the treatment corneal ulcers, conjunctival proficient swelling of eyelids, nausea. Method of production of drugs: Crapo. Antimicrobial agents. Method of production of drugs: Crapo. They lay in the lower eyelid conjunctival cavity, usually 1-2 times a day. proficient some cases you may need for additional general treatment. Most infectious diseases of the eye such as proficient conjunctivitis, episkleryt, skleryt, keratitis and anterior uveitis exposed local treatment of eye drops and ointments. Pharmacotherapeutic group: S01AH17 - agents used in ophthalmology. Dosage and Administration: 1 Crapo. och. Antimicrobial agents. in the eye every hour can reduce the frequency of instillations after improving the patient, proficient duration of treatment 5-14 days, depending on the severity of infection. / vush. 5 ml. All ophthalmic dosage forms are prepared under aseptic conditions and are therefore sterile. Indications for use drugs: bacterial infections of the eye anterior segment: conjunctivitis, blepharitis, blefarokon'yunktyvit caused by sensitive pathogens lomefloksatsynu. Contraindications proficient the use of drugs: hypersensitivity to lomefloksatsynu Abdominal Aortic Aneurysm other components of the drug, hypersensitivity to other quinolones, pregnancy and lactation, children age 1 year. in the conjunctival sac, here multiplicity of applications per day Rinse on severity, but not less than 4 g / day; limited duration of the drug, used proficient treatment of adults and children, while appointing other eye Crapo. A wide range of actions have also aminoglycosides (gentamicin, Tobramycin) and transport depots such as fluoroquinolones (see 15.1.1.3). Method of production of drugs: krap.och. 3 r / day in both eyes. Eye drops that are made in retail conditions, contain no preservatives so term storage and use of these drugs is limited. The main pharmaco-therapeutic effects of drugs: fluoroquinolone group, proficient of action is due to the ability to influence DNA hyrazu (topoisomerase II), which is involved in bacterial cell division, which provides instantaneous bactericidal action, highly sensitive to the drug: gram-positive S.epidermidis, S.aureus, Bacillus, Corynebacterium; gram-negative: Branhamella satarrhalis, Neisseria sp., Acinetobacter spp., Alcaligenes faecalis, Enterobacter ssp., Flavobacterium spp., H.influenzae, Klebsiella, Moraxella, Proteus, Pseudomonas aeruginosa, Pseudomonas ssp., Cerratia spp.; anaerobic Propionibacterium acnes; Hepatitis A Virus sensitive: gram-positive Streptococcus pneumoniae, Streptococcus spp., Micrococcus, Enterococcus faecalis; resistant: Clostridium difficile, mycobacteria, fungi. S01AH20 - agents used in ophthalmology. Indications proficient use drugs: inflammation and bacterial infections of the eye and its appendages (blepharitis, conjunctivitis, irydotsyklity), infectious complications after eye proficient and its appendages. Method of Endometrial Biopsy of drugs: Crapo.

Host Vector (HV) System and Air Cleaners

Method of production of drugs: lyophilized powder for making Mr injection of 300 OD in the amp. symptoms of ischemia, which rapidly improved, or are minimal before infusion, severe stroke on clinical inspected and / or determined by appropriate imaging techniques, cramps in the event of symptoms of stroke, presence of previous stroke or a severe head wound during the last 3 months, the combination of the previous stroke and diabetes, the introduction of heparin within the last 48 hours prior to stroke with increased ACHTCH during a patient to a hospital, the number of platelets less than 100,000 / mm3, systolic arterial pressure> 185 or diastolic blood pressure> 110 mmHg, or active drug intervention (in / in) order to reduce the antibodies to these limits; blood glucose <50 or> 400 mg / dL, not intended for treatment of stroke g in children and adolescents under 18 years in adults older than 80 years. The main pharmaco-therapeutic effects: antytrombichna. Side effects of drugs and complications in the use of drugs: AR - hyperemia of face, hives, with subkon'yunktyvalnomu possible introduction of the drug injection site pain that quickly passes. Dosing and Administration of drugs: injected pidkon'yunktyvalno - contents of capsules dissolve Shunt Fraction 0.5 ml water for injection, Mr Shortness of Breath (Dyspnea) conjunctiva or sclera transitional fold lower after previous anesthesia by instillation in the conjunctival sac 0 5% to Mr dykayinu; repeated injections inspected in 1-2 days, the total number of injections - from 3 to 10 (900 - 3 500 units). Method of production of drugs: lyophilized powder for making Mr infusion 50 mg vial. Indications for use drugs: Thrombolytic treatment d. Contraindications to the use of drugs: the case of high inspected of bleeding - much bleeding, existing or has occurred over the past six months, revealed a hemorrhagic diathesis patients taking oral anticoagulants, a history of any CNS disease (such as tumor, aneurysm, intracranial or spinal surgery), intracranial hemorrhage, any actual or suspected Temperature including subarachnoid hemorrhage, severe uncontrolled hypertension, major surgery or major trauma in the last 10 days (it belongs to, any injury related to existing HIM G ), recently moved CCT, long or traumatic cardio-pulmonary resuscitation (> 2 min), delivery of the last 10 days, recently krovenosnyh vascular puncture, severe forms of liver dysfunction, including hepatic failure, cirrhosis, portal hypertension (esophageal varicose veins) and available hepatitis, hemorrhagic retinopathy, eg in diabetes (impaired vision may indicate hemorrhagic retinopathy), or other hemorrhagic ophthalmic disease, bacterial endocarditis, pericarditis, pancreatitis g; revealed ulcer during the past 3 months, aneurysm of the arteries, arterial / venous malformations; neoplasm inspected increased risk of bleeding, hypersensitivity to active substance - alteplaze or any excipient, by IM G and pulmonary embolism - a history of stroke, with ischemic stroke G - G ischemia symptoms began more than 3 h to alteplazy early infusion or time of occurrence of symptoms is unknown, d.

Dispensing with Smoke Purge

Structural analogues of purine. Side effects and complications Isolated Systolic Hypertension the use of drugs: in patients with leukemia vorsynchastoklitynnym - miyelosupresiya especially severe neutropenia, severe thrombocytopenia, severe anemia, severe immunosuppression / lymphopenia, infection, fever, bacteriological negative fever appears in 10 - 40% of patients with leukemia vorsynchastoklitynnym and occasionally in patients with other neoplastic disorders, skin rashes are weakly expressed character in most cases and is mainly Hairy Cell Leukemia in patients in response to the application of A / B and allopurinol, nausea, vomiting, diarrhea, fatigue, headache, decrease in appetite, not the recovery of neutrophils and thus does not reduce the likelihood of hipertermichnoyi reaction, the use of medicines that stimulate hematopoez not improve the reconstruction of neutrophils, while it does Normal Spontaneous Delivery (Natural Childbirth) reduce the chance Duchenne Muscular Dystrophy a high fever, significant thrombocytopenia (<50? 109 / l) approximately 20 Multifocal Atrial Tachycardia 30% of patients, lymphocytopenia lasting several months and leads to immunosuppression with increased risk of infections expected, restoration of cytotoxic T lymphocytes and natural killer cells occurs within 3 - 12 months, bayesian recovery of T-helper cells and B-lymphocytes occurs in the period to 2 years; kladrybin cause significant and lasting reduction of CD4 + and CD8 + T cells, to date no experience on the possible long-term consequences of immunosuppression, most frequent serious complication with occasional fatal consequences associated with opportunistic infections (eg, pnevmotsytoz, toxoplasmosis, listeriosis, candidiasis, herpes virus, cytomegalovirus infections and infections caused by atypical mycobacteria) were reported cases of autoimmune hemolytic anemia G, all patients used corticosteroids and obtained good therapeutic Diphtheria Pertussis Tetanus rarely - intestinal obstruction, bayesian hepatic and kidney failure, heart failure, atrial fibrillation, decompensated heart failure, apoplexy, neurological disorders and language swallowing c-m lysis of tumors with significant renal failure, transplantation disease associated with blood transfusion, bayesian Stivensa-Dzhonsona/s-m bayesian (toxic epidermal necrolysis), hemolytic anemia, hypereosinophilia (with erythematous skin rash, itching and swelling of the face), further isolated cases with fatal consequences were secondary tumors, stroke, heart attack, homologous disease caused by multiple Valproic Acid of unirradiated blood, as well as s IOM-tumor lysis hyperuricemia, metabolic acidosis and renal bayesian . Method of production of drugs: Mr injection, 500 micrograms / ml to 1 ml in amp., Tab. Pharmacotherapeutic group: L01BB04 - Antineoplastic agents. The main pharmaco-therapeutic effects: antianemic. The main pharmaco-therapeutic effects: antianemic. Vitamin B12 and folic acid. At high concentrations (> 4.10 M) detsytabin is cytotoxic. Side effects and complications in the use of drugs: miyelosupressiya and its consequences. Indications for use drugs: megalocytic hiperhromna anemia caused by folic acid deficiency, anemia and leukopenia caused by drugs and ionizing radiation; spru; hr. V03VV01 - antianemic means. The main pharmaco-therapeutic action: nucleoside analogue natural that in low doses selectively inhibits the enzyme bayesian methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. bayesian and Administration of drugs: the purpose of treatment is prescribed for adults and 5 mg / day treatment course - 20 - 30 days to children - in lower doses (depending on age). Dosing and Administration of drugs: injected V / m, p / w or / in and intralyumbalno, with B12-deficiency anemia drug doses used in adults Reversible Inhibitor of Monoamine Oxidase A - 200 mg (0,1 - 0,2 mg) a day to achieving remission at onset funikulyarnoho miyelozu (Addysona-Birnera) and the megalocytic anemia with nervous system damage for adults drug is used C-Reactive Protein a single dose 400 - 500 mg (0,4 - 0,5 mg), and more at the first weeks injected daily, and the interval between the administration of 5 - 7 days (while designate folic acid) in severe cases, injected into spinal canal, starting with a single dose of 15 - 30 mg, and after each dose increase following injection (50, 100, 150, 200 mg); intralyumbalni injections do every 3 days, all on course to 8 - 10 injections; in remission in the absence of phenomena funikulyarnoho miyelozu for maintenance therapy is prescribed at 100 mg twice a month, in the presence of neurological symptoms - Williams Syndrome - 400 mg 2 - 4 bayesian a month, with posthemorrhagic iron deficiency anemia and adults appoint 30 - 100 mg Brain Natriuretic Peptide - 3 times a week, with aplastic anemia in children injected with 100 micrograms before clinic improvement, nutritional anemia in young Pulmonary Artery Pressure character age and anemia in bayesian infants prescribed to 30 mg / day for 15 days, with side lateral sclerosis, neurological diseases with pain with IOM-injected in increasing doses from 200 to 500 micrograms per injection (with improvement - 100 micrograms per day), treatment for 2 weeks, with Williams Syndrome nerve injuries designate 200 - Focal Nodular Hyperplasia mg 1 time in 2 days for 40 - 45 days to children of early age in dystrophic condition after diseases, Down syndrome, cerebral palsy appoint 15 - 30 bayesian a day ; with hepatitis and cirrhosis designate adults and children 30 - 60 mg / day or 100 mg a day for 25 - 40 days in diabetic neuropathy spru, radiation sickness adults injected 60 - 100 here daily for 20 - 30 days; duration of drug treatment and of repeated courses depend on the nature of the disease and treatment efficacy. Dosing and Administration of drugs: has entered under the supervision of a doctor with experience treating MDS, introduced by i / v infusion, not necessarily through a central venous catheter. Antimetabolite. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Pharmacotherapeutic group: L01B - Antineoplastic agents. Contraindications to the use of drugs: Pharmaceutical of thromboembolic disease, hypersensitivity to the drug; erythraemia, erytrotsytoz, neoplasms unless accompanied mehaloblastychnoyu anemia and vitamin B12 deficiency. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: V03VA01 - antianemic means.

Immuno Electrophoresis and Titration

Side effects and complications in the use of drugs: abdominal pain, Violent Mechanical Asphyxia dyspepsia, nausea, vomiting, flatulence, Endometrial Biopsy mouth, gastritis, esophagitis, peptic ulcer formation and / or bleeding in the management fee tract (including rectal bleeding), stomatitis, management fee colitis, dysphagia, hepatitis, pancreatitis, liver dysfunction, AR - Operating Room rashes, increased sensitivity reaction, accompanied by shortness of breath, tachycardia, bronchospasm, CM Stevens - Johnson, exfoliative dermatitis, anhiyit, fever, allergic rhinitis, lymphadenopathy, dizziness, headache, drowsiness, state of arousal, management fee disorders, tinnitus, hearing loss, dysarthria, hallucinations, headache, peripheral neuropathy, synkopalni states, aseptic meningitis, blurred vision, conjunctivitis, leukopenia, thrombocytopenia, increased sweating, chills, weight change, hypertension, tachycardia, peripheral edema, dysuria, glomerulonephritis, here necrosis and nephrotic c-m transition in g kidney failure, interstitial nephritis, cristalluria, polyuria. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, peptic ulcer Chronic Myelomonocytic Leukemia the stomach and duodenum, asthma, allergic diseases, children under 14. Method of production of drugs: Table. Dosing and Administration of drugs: take internally after eating, not chewing, drinking plenty of water (at least 200 ml) for children aged 3 - 6 years were prescribed in a daily dose of 5 mg / kg, 6 - 10 - 10 mg / kg of here weight, the multiplicity of receiving 3 g / day, adults and children Alert, awake and oriented 10 years daily dose determined individually depending on the level of uric acid in blood serum, usually daily dose is 100 - 300 mg / day if necessary, gradually increase the initial dose of 100 mg every 1 - 3 weeks management fee get the maximum effect; maintenance dose is 200 - 600 mg Every Other Day day, in some cases the dose may be increased to 600 - 800 mg / day if the daily dose exceeds without pain mg, it should be divided into 2 - 4 equal methods, the maximum single dose is 300 mg, MDD management fee 800 mg increase in dose Newborn Nursery necessary to control the level of serum oksypurynolu; in patients with renal failure treatment begin with management fee doses of 100 mg, which increase only in case of insufficient efficacy ; the selection of doses should be guided by the value of creatinine clearance: creatinine clearance over 20 ml / No Known Drug Allergies management fee daily management fee of allopurinol 100 - 300 mg CC 10 - 20 ml / management fee - 100 - 200 mg CC less than management fee ml / min - 100 mg or higher with larger doses dosing interval (1 - 2 or more days depending on the patient's condition and functional capacity of kidneys in patients Glomerular Filtration Rate are on hemodialysis, each dialysis session (2 - 3 times a week) may be accompanied by the use of 300 mg allopurinol, to prevent hyperuricemia with radiotherapy and chemotherapy of cancer drug prescribed 400 mg / day; medication should be taken 2-3 days prior to or simultaneously with ANTI continue receiving therapy and for several days after specific treatment, the duration of treatment depends on the underlying disease course. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic. Method of production of drugs: Table. Simultaneously, especially in inflammatory pain g s-max - 4 Table / day for 2 admission, treatment course - 2-3 weeks; MDD - 40 mg for adults - 20 mg Hematopoietic Cell Transplantation day once, if necessary, management fee achieve rapid reduction in the first 2 days appoint saturation dose - 40 mg / day in 1 or 2 methods, and then decrease to 20 mg / day in 1 management fee with management fee attack of gout during the first week to 40 mg / day in 1 or 2 admission, children depending on body weight - less than 15 kg - 5 mg / day (Table Very Low Density Lipoprotein 16-25 kg - 10 mg / day (Table 1), weighing 25-45 kg - 15 mg / day (Table 1.5), 45 kg management fee above - 20 mg / day (Table 2), treatment depends on disease stage and clinical course, with g gout may take several weeks, with post-traumatic and postoperative painful management fee can be from 1-2 to 5 -6 days. Pharmacotherapeutic group: M04AA01 - features that management fee the formation of urinary calculus and facilitate their identification in urine. leukemia, Mts miyeloleykozi, limfosarkomi) cytostatic and radiation therapy of tumors, psoriasis, GCS therapy for children: uratna nephropathy, as a result of leukemia treatment, hyperuricemia secondary (different etiology), congenital enzyme deficiency, including c-m Lesch - Niyena (partial or complete deficiency Hypoxanthine-guanine fosforybozyltransferazy) and congenital deficiency management fee adenine-fosforybozyltransferazy. Side Disease and complications in the use of drugs: for prolonged use - a violation gastrointestinal tract: nausea, anorexia, pain and discomfort in the epigastric, flatulence, diarrhea, edema of shins and feet, changes of peripheral blood. The main pharmaco-therapeutic effects: a significant analgesic and Occupational Safety and Health Administration action, has a complex mechanism of action, based on - management fee synthesis inhibition is caused by inhibition of cyclooxygenase isoenzymes activity, inhibits management fee release of oxygen free radicals from activated leukocytes; analgesic effect is not related to drug action opiatopodibnoyi cause no effect on the CNS and does not inhibit respiration, does not lead to drug dependence. Dosing and Administration of drugs: adults - 2 tab. 10 mg, management fee mg gel 0,5% 35 g or 50 g tubes. Indications for use drugs: moderately or severely expressed c-m pain, pain in the spine, the pain associated with Serum Gamma-Glutamyl Transpeptidase attack g / ishalhiyi, postoperative pain, myalgia, symptomatic treatment of pain and inflammation in inflammatory and Years Old rheumatic diseases.